Project Oncology®
Showcasing major breakthroughs in cancer care from worldwide clinical trials, Project Oncology® educates and assists the healthcare professionals who dedicate their lives to helping patients fight cancer.
Here you’ll find leading oncologists discuss and share essential cancer care strategies for all different types of cancer. And as worldwide clinical trials continue to explore new screening tests and discover novel treatment options, you can rest assured that you’ll always catch the latest in cancer research with Project Oncology®.
- Update frequency
- every 5 days
- Episodes
- 347
- Years Active
- 2015 - 2025
Subcutaneous Cancer Immunotherapy at Home: Transforming Trials and Patient Care
As cancer treatment continues to evolve, at-home subcutaneous immunotherapy is at the forefront of decentralized care and research. Here to share his insights on how …
Bringing Cancer Care Home: How Subcutaneous Immunotherapy Can Help Ease the Burden
As immunotherapy becomes a cornerstone for treating a growing number of solid tumors, reducing the logistical burden of in-office care is essential. Fortunately, the …
Unpacking the Logistics of At-Home Subcutaneous Cancer Immunotherapy Delivery
Despite the promising benefits for cancer patients, the at-home administration of subcutaneous immunotherapy poses complex operational and logistical challenges, like…
Unpacking the Logistics of At-Home Subcutaneous Cancer Immunotherapy Delivery
Despite the promising benefits for cancer patients, the at-home administration of subcutaneous immunotherapy poses complex operational and logistical challenges, like…
Bringing Cancer Care Home: How Subcutaneous Immunotherapy Can Help Ease the Burden
As immunotherapy becomes a cornerstone for treating a growing number of solid tumors, reducing the logistical burden of in-office care is essential. Fortunately, the …
Investigating At-Home Subcutaneous Atezolizumab for NSCLC: An Ongoing Study
Can the immune checkpoint inhibitor atezolizumab be safely administered subcutaneously at home for patients with non-small cell lung cancer (NSCLC)? That’s the exact …
Investigating At-Home Subcutaneous Atezolizumab for NSCLC: An Ongoing Study
Can the immune checkpoint inhibitor atezolizumab be safely administered subcutaneously at home for patients with non-small cell lung cancer (NSCLC)? That’s the exact …
Trial in Progress: Phase 3 MoonRISe-3 Study
This series of video briefs features Dr. Neal Shore reporting from AUA 2025 in Las Vegas. Tune in for timely updates on innovatively delivered intravesical therapies for non–muscle invasive bladder c…
First Results From Cohort 4 of the SunRISe-1 Trial
This series of video briefs features Dr. Neal Shore reporting from AUA 2025 in Las Vegas. Tune in for timely updates on innovatively delivered intravesical therapies for non–muscle invasive bladder c…
Trial in Progress: Phase 3 MoonRISe-3 Study
This series of video briefs features Dr. Neal Shore reporting from AUA 2025 in Las Vegas. Tune in for timely updates on innovatively delivered intravesical therapies for non–muscle invasive bladder c…
First Results From Cohort 4 of the SunRISe-1 Trial
This series of video briefs features Dr. Neal Shore reporting from AUA 2025 in Las Vegas. Tune in for timely updates on innovatively delivered intravesical therapies for non–muscle invasive bladder c…
HER2 Testing: The Evolving Role of Immunohistochemistry (IHC)
Guest: Christian Rolfo, MD, PhD
Guest: Charlie Gourley, MD, PhD
In this on-demand replay of a recent interactive webinar, renowned experts Prof. …
HER2 Testing: The Evolving Role of Immunohistochemistry (IHC)
Guest: Christian Rolfo, MD, PhD
Guest: Charlie Gourley, MD, PhD
In this on-demand replay of a recent interactive webinar, renowned experts Prof. …
Targeting CD123 in AML: The Latest Therapeutic Advancements
Guest: Naval Daver, MD
Not only is CD123 one of the most common antigens expressed on the surface of acute myeloid leukemia (AML) tumors, but it’s also associa…
Targeting CD123 in AML: The Latest Therapeutic Advancements
Guest: Naval Daver, MD
Not only is CD123 one of the most common antigens expressed on the surface of acute myeloid leukemia (AML) tumors, but it’s also associa…
Advancing Cancer Care: Key Considerations for Subcutaneous Immunotherapies
Guest: Matthew Hadfield, MD
Subcutaneous cancer immunotherapies may offer a faster, more resource-efficient alternative to intravenous administr…
Advancing Cancer Care: Key Considerations for Subcutaneous Immunotherapies
Guest: Matthew Hadfield, MD
Subcutaneous cancer immunotherapies may offer a faster, more resource-efficient alternative to intravenous administr…
Navigating a Positive MCED Test and Negative Diagnostic Workup: Real-World Data
Guest: Eric Klein, MD
With an urgent need to screen for cancer, clinical trials have shown that the multi-cancer early detection (MCED) test Gal…
Navigating a Positive MCED Test and Negative Diagnostic Workup: Real-World Data
Guest: Eric Klein, MD
With an urgent need to screen for cancer, clinical trials have shown that the multi-cancer early detection (MCED) test Gal…
Antibody-Drug Conjugates in Bladder Cancer: Guideline Updates and Adverse Event Management
Guest: Shilpa Gupta, MD
New understanding of molecular targets has helped transform invasive bladder cancer treatment, and guidelines now recom…